ZLDPF:OTC-Zealand Pharma A/S (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 129.35

Change

0.00 (0.00)%

Market Cap

USD 7.82B

Volume

3.17K

Analyst Target

USD 36.83
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 641.36B
CMXHF CSL Limited

-1.00 (-0.52%)

USD 95.97B
CSLLY CSL Ltd

N/A

USD 95.20B
UCBJY UCB SA ADR

-0.23 (-0.30%)

USD 28.14B
UCBJF UCB SA

N/A

USD 27.96B
ARGNF argenx SE

N/A

USD 26.71B
GNMSF Genmab A/S

-13.67 (-5.37%)

USD 16.55B
IVBIY IVBIY

N/A

USD 8.23B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.55B
REGMF RemeGen Co. Ltd

N/A

USD 6.81B

ETFs Containing ZLDPF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 132.43% 92% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 132.43% 92% A 95% A
Trailing 12 Months  
Capital Gain 274.38% 95% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 274.38% 95% A 97% N/A
Trailing 5 Years  
Capital Gain 546.75% 93% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 546.75% 93% A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 42.23% 69% C- 75% C
Dividend Return 42.23% 69% C- 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 79.65% 49% F 38% F
Risk Adjusted Return 53.02% 97% N/A 88% B+
Market Capitalization 7.82B 97% N/A 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector